For companies looking for a product-life-cycle extension or a new drug delivery system, Noven Pharmaceuticals is the strategic partner of choice. Our DOT Matrix^® technology, patented through 2014, represents the latest generation drug-in-adhesive platform for transdermal drug delivery. This technology is a valuable life-cycle management asset for line-extensions of existing products, as well as for transdermal delivery of new drugs. DOT Matrix technology can increase the value of our partners’ product portfolios through development collaborations and licensing arrangements for a fee or on a risk-sharing basis.

For additional information, contact Noven Business Development.